Plasmodium Falciparum Malaria
Conditions
Keywords
Efficacy, Artemether/lumefantrine, Malaria, Children
Brief summary
Artemether-lumefantrine has been used in Tanzania as first-line treatment for uncomplicated malaria since 2007. Nonetheless, a report of increased proportion of patients with parasitaemia on day 1 following treatment with artemisinin based combination therapies has emerged from Kenya. Similarly, resistance against artemisinins has been confirmed in South-East Asia and it can spread to Africa. Therefore, the purpose of this study was to assess the efficacy of Artemether-lumefantrine for the treatment of uncomplicated malaria among children after five years of wide scale use of the drug in Tanzania.
Detailed description
Artemisinin based combination therapies (ACTs) are currently recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated malaria in all malaria endemic countries including Tanzania, that adopted the policy in 2007. ACTs have proven to be highly efficacious in different parts of the world with different malaria endemicity. Artemisinins clear asexual parasites rapidly and they are also potent against P. falciparum gametocytes, hence reducing disease transmission and spread of drug resistance. Nonetheless, a report in Kenya shows an increase in proportion of patients with parasitaemia on day 1. Most recently, resistance against artemisinins has been confirmed in four countries of South-East Asia, and it may spread to Africa. In order to safeguard ACTs life span, WHO recommends all suspected malaria cases to be confirmed with parasitological diagnosis, followed by prompt treatment with effective antimalarials. It also emphasizes on the need to conduct efficacy studies for the first and second line antimalarial treatments after every two years so as to be able to detect resistance early on its course. Therefore, based on this notion, this study aimed to assess the therapeutic efficacy of Artemether/Lumefantrine among children with uncomplicated falciparum malaria in Bagamoyo district, five years after its wide scale use in Tanzania.
Interventions
DRUGArtemether-lumefantrine
Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
Sponsors
Karolinska Institutet
Richard Mwaiswelo
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 120 Months
Healthy volunteers
No
Inclusion criteria
* Mono-infection with P. falciparum * Parasitaemia level of 2000 - 200,000/μL * Absence of danger signs or signs of severe malaria * Axillary temperature ≥ 37.5°C or history of fever 24 hours prior to coming to the facility * Absence of other concomitant infections like pneumonia which can cause fever * No use of antimalarial drug two weeks prior to the study * Consent to comply to the protocol.
Exclusion criteria
* Presence of general danger signs or signs of severe falciparum malaria * Severe malnutrition * Febrile condition due to diseases other than malaria, such as measles, acute lower respiratory infection or other known chronic diseases * Regular medication which might interfere with antimalarial pharmacokinetics * History of hypersensitivity reactions or contraindications to any medicine being used in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients without parasitaemia on day 42. | 42 Days | Proportion of patients without parasitaemia or with new infection as corrected by molecular genotyping on day 42 will be used to calculate the efficacy of the trial medicine. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma lumefantrine concentration | 7 days and 14 days | Mean plasma lumefantrine concentration among patients on day 7 and day 14 following treatment with artemether/lumefantrine as a predictor of cure rate. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Proportional of patients without parasitaemia on day 42 | 42 days | Proportion of patients without parasitaemia on day 42 as purely assessed by molecular genotyping of all collected samples on this day, differentiate between recrudescence and new infection and use it to calculate the efficacy of the trial medicine. |
Countries
Tanzania
Outcome results
None listed